b*****h
发帖数: 783 | 1 good news or bad news coming? | v**********m
发帖数: 5516 | 2 what's happening on dndn?
【在 b*****h 的大作中提到】
: good news or bad news coming?
| K********g
发帖数: 9389 | 3 好像解决了啥问题，好消息。
不知道回到多少，马拉个巴兹，刚想买呢。 | v**********m
发帖数: 5516 | 4 由于这个？
Dendreon Agrees to Sell VICTRELIS(TM) (boceprevir) Royalty Interest for $125
Million
SEATTLE, Dec 06, 2011 (BUSINESS WIRE) -- Dendreon Corporation DNDN -0.11%
today announced that it has agreed to sell for $125 million in cash its
royalty interest related to intellectual property licensed to Schering-
Plough Ltd. and Schering Corporation (collectively Schering, each now a
wholly owned subsidiary of Merck & Co., Inc.) and associated with VICTRELIS(
TM) (boceprevir), a treatment for chronic hepatitis C. The royalty interest
was acquired by CPPIB Credit Investments Inc., a wholly-owned subsidiary of
CPP Investment Board (CPPIB). The transaction is expected to close in
December 2011. The intellectual property related to VICTRELIS was co-
developed by Corvas International, Inc. and Schering and, was acquired by
Dendreon in July 2003.
"The sale of the VICTRELIS royalty interest allows the Company to strengthen
our cash position, and enables us to further invest in our core business
initiatives," said Greg Schiffman, executive vice president and chief
financial officer.
VICTRELIS, a hepatitis C virus protease inhibitor, was approved by the U.S.
Food and Drug Administration (FDA) on May 13, 2011 for the treatment of
chronic hepatitis C virus (HCV) genotype 1 (G1) infection, in combination
with peginterferon alfa and ribavirin (P/R), in adult patients (18 years and
older) with compensated liver disease, including cirrhosis, who are
previously untreated or who have failed previous interferon and ribavirin
therapy. VICTRELIS was approved for the same indicated use by the European
Commission (EC) on July 18, 2011.
Centerview Partners is acting as financial advisor and WilmerHale is acting
as legal advisor to Dendreon. Covington & Burling LLP is acting as legal
advisor to CPPIB Credit Investments Inc.
About CPP Investment Board
The CPP Investment Board is a professional investment management
organization that invests the funds not needed by the Canada Pension Plan to
pay current benefits on behalf of 17 million Canadian contributors and
beneficiaries. In order to build a diversified portfolio of CPP assets, the
CPP Investment Board invests in public equities, private equities, real
estate, inflation-linked bonds, infrastructure and fixed income instruments.
Headquartered in Toronto, with offices in London and Hong Kong, the CPP
Investment Board is governed and managed independently of the Canada Pension
Plan and at arm's length from governments. At September 30, 2011, the CPP
Fund totaled $152.3 billion. For more information about the CPP Investment
Board, please visit www.cppib.ca .
About Dendreon
Dendreon Corporation is a biotechnology company whose mission is to target
cancer and transform lives through the discovery, development,
commercialization and manufacturing of novel therapeutics. The Company
applies its expertise in antigen identification, engineering and cell
processing to produce active cellular immunotherapy (ACI) product candidates
designed to stimulate an immune response in a variety of tumor types.
Dendreon's first product, PROVENGE(R) (sipuleucel-T), was approved by the
FDA in April 2010. Dendreon is exploring the application of additional ACI
product candidates and small molecules for the potential treatment of a
variety of cancers. The Company is headquartered in Seattle, Washington and
is traded on the NASDAQ Global Market under the symbol DNDN. For more
information about the Company and its programs, visit http://www.dendreon.com .
This news release contains forward-looking statements that are subject to
risks and uncertainties. Factors that could affect these forward-looking
statements include, but are not limited to, developments affecting Dendreon'
s business and prospects, including progress on the commercialization
efforts for PROVENGE. Information on the factors and risks that could affect
Dendreon's business, financial condition and results of operations are
contained in Dendreon's public disclosure filings with the U.S. Securities
and Exchange Commission, which are available at www.sec.gov . Dendreon
cautions investors not to place undue reliance on the forward-looking
statements contained in this press release. All forward-looking statements
are based on information currently available to Dendreon on the date hereof,
and Dendreon undertakes no obligation to revise or update these forward-
looking statements to reflect events or circumstances after the date of this
press release, except as required by law.
SOURCE: Dendreon Corporation | b*****h
发帖数: 783 | 5 开始卖家当筹钱了，比稀释股票强
【在 K********g 的大作中提到】
: 好像解决了啥问题，好消息。
: 不知道回到多少，马拉个巴兹，刚想买呢。
| v**********m
发帖数: 5516 | 6 这个不如去借钱。
【在 b*****h 的大作中提到】
: 开始卖家当筹钱了，比稀释股票强
| b*****h
发帖数: 783 | 7 这个时候借钱，就要签订不平等条约。。还是卖掉一些其他资产，集中力量搞好他们的
主业比较好。
【在 v**********m 的大作中提到】
: 这个不如去借钱。
|
|
